A multi-institutional retrospective study of the efficacy and safety of immune checkpoint blockade for patients with non-small cell lung cancer and pre-existing autoimmune disease (NEJ047)
Not Applicable
Completed
- Conditions
- Patients with non-small cell lung cancer and pre-existing autoimmune disease
- Registration Number
- JPRN-UMIN000040512
- Lead Sponsor
- orth East Japan Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Ratio of acute exacerbation of AID in patients with NSCLC and AID who received ICB 2. Rate of serious immune related adverse events (irAE) in patients with NSCLC and AID who received ICB
- Secondary Outcome Measures
Name Time Method 1. Objective response rate (ORR) 2. Progression-free survival (PFS) 3. Overall survival (OS) 4. Time to treatment failure (TTF)